380 related articles for article (PubMed ID: 29902200)
1. ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
Ratai EM; Zhang Z; Fink J; Muzi M; Hanna L; Greco E; Richards T; Kim D; Andronesi OC; Mintz A; Kostakoglu L; Prah M; Ellingson B; Schmainda K; Sorensen G; Barboriak D; Mankoff D; Gerstner ER;
PLoS One; 2018; 13(6):e0198548. PubMed ID: 29902200
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Ratai EM; Zhang Z; Snyder BS; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Gilbert MR; Sorensen AG; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):936-44. PubMed ID: 23645534
[TBL] [Abstract][Full Text] [Related]
3. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.
Gerstner ER; Zhang Z; Fink JR; Muzi M; Hanna L; Greco E; Prah M; Schmainda KM; Mintz A; Kostakoglu L; Eikman EA; Ellingson BM; Ratai EM; Sorensen AG; Barboriak DP; Mankoff DA;
Clin Cancer Res; 2016 Oct; 22(20):5079-5086. PubMed ID: 27185374
[TBL] [Abstract][Full Text] [Related]
4. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
[TBL] [Abstract][Full Text] [Related]
5. Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI.
Feng A; Yuan P; Huang T; Li L; Lyu J
Acad Radiol; 2022 Sep; 29(9):1320-1331. PubMed ID: 34896001
[TBL] [Abstract][Full Text] [Related]
6. Major Metabolite Levels of Preoperative Proton Magnetic Resonance Sectroscopy and Intraoperative Fluorescence Intensity in Glioblastoma.
Tian HL; Zu YL; Wang CC; Lin T; Guo ZT; Jiang B; Yin X; Guo WQ; Wang ZG
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):511-517. PubMed ID: 28877829
[TBL] [Abstract][Full Text] [Related]
7. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
8. In vivo differentiation of aerobic brain abscesses and necrotic glioblastomas multiforme using proton MR spectroscopic imaging.
Lai PH; Weng HH; Chen CY; Hsu SS; Ding S; Ko CW; Fu JH; Liang HL; Chen KH
AJNR Am J Neuroradiol; 2008 Sep; 29(8):1511-8. PubMed ID: 18499784
[TBL] [Abstract][Full Text] [Related]
9. [Metabolic imaging to follow stereotactic radiation of gliomas -- the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT].
Lichy MP; Henze M; Plathow C; Bachert P; Kauczor HU; Schlemmer HP
Rofo; 2004 Aug; 176(8):1114-21. PubMed ID: 15346287
[TBL] [Abstract][Full Text] [Related]
10. Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors.
Server A; Josefsen R; Kulle B; Maehlen J; Schellhorn T; Gadmar Ø; Kumar T; Haakonsen M; Langberg CW; Nakstad PH
Acta Radiol; 2010 Apr; 51(3):316-25. PubMed ID: 20092374
[TBL] [Abstract][Full Text] [Related]
11. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Nelson SJ; Li Y; Lupo JM; Olson M; Crane JC; Molinaro A; Roy R; Clarke J; Butowski N; Prados M; Cha S; Chang SM
J Neurooncol; 2016 Oct; 130(1):171-179. PubMed ID: 27535746
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
[TBL] [Abstract][Full Text] [Related]
13. Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?
Tensaouti F; Desmoulin F; Gilhodes J; Roques M; Ken S; Lotterie JA; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lubrano V; Péran P; Cohen-Jonathan Moyal E; Laprie A
Radiother Oncol; 2023 Jun; 183():109665. PubMed ID: 37024057
[TBL] [Abstract][Full Text] [Related]
14. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.
Bisdas S; Ritz R; Bender B; Braun C; Pfannenberg C; Reimold M; Naegele T; Ernemann U
Invest Radiol; 2013 May; 48(5):295-301. PubMed ID: 23296081
[TBL] [Abstract][Full Text] [Related]
15. Amid proton transfer (APT) and magnetization transfer (MT) MRI contrasts provide complimentary assessment of brain tumors similarly to proton magnetic resonance spectroscopy imaging (MRSI).
Su C; Zhao L; Li S; Jiang J; Cai K; Shi J; Yao Y; Ao Q; Zhang G; Shen N; Hu S; Zhang J; Qin Y; Zhu W
Eur Radiol; 2019 Mar; 29(3):1203-1210. PubMed ID: 30105412
[TBL] [Abstract][Full Text] [Related]
16. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor.
Toyonaga T; Yamaguchi S; Hirata K; Kobayashi K; Manabe O; Watanabe S; Terasaka S; Kobayashi H; Hattori N; Shiga T; Kuge Y; Tanaka S; Ito YM; Tamaki N
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):611-619. PubMed ID: 27752745
[TBL] [Abstract][Full Text] [Related]
17. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
Raizer JJ; Koutcher JA; Abrey LE; Panageas KS; DeAngelis LM; Lis E; Xu S; Zakian KL
J Neurooncol; 2005 Jan; 71(2):173-80. PubMed ID: 15690135
[TBL] [Abstract][Full Text] [Related]
18. Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy.
Balmaceda C; Critchell D; Mao X; Cheung K; Pannullo S; DeLaPaz RL; Shungu DC
J Neurooncol; 2006 Jan; 76(2):185-91. PubMed ID: 16151595
[TBL] [Abstract][Full Text] [Related]
19. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.
Li X; Jin H; Lu Y; Oh J; Chang S; Nelson SJ
NMR Biomed; 2004 Feb; 17(1):10-20. PubMed ID: 15011246
[TBL] [Abstract][Full Text] [Related]
20. The Diagnostic Value of Apparent Diffusion Coefficient and Proton Magnetic Resonance Spectroscopy in the Grading of Pediatric Gliomas.
Yao R; Cheng A; Liu M; Zhang Z; Jin B; Yu H
J Comput Assist Tomogr; 2021 Mar-Apr 01; 45(2):269-276. PubMed ID: 33346568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
